XNK Therapeutics has announced the appointment of Hugo Petit as Chief Financial Officer (CFO) and member of the company’s leadership team.
“We are very pleased to have Hugo join us as XNK’s new CFO. His wealth of financial experience, particularly in the life sciences sector, will strengthen the organization as we continue to grow the company“, said Johan Liwing, CEO of XNK Therapeutics.
Hugo Petit has held senior positions within finance and business development since 2005, including CFO at MedCap and OxThera. Before joining XNK Therapeutics, he was CFO at Renewcell. Hugo has also worked as a management consultant at McKinsey & Company. Hugo holds an MBA in economics and executive management from Uppsala University, Sweden.
“XNK is in a unique position within the space of autologous NK cell-based therapies and has ambitious growth targets. I really look forward to supporting XNK in all possible ways on its exciting journey,” says Hugo Petit.
Hugo will replace current CFO Hans Ericson, with whom he has worked closely over the last few months.
Photo: XNK Therapeutics